TY - JOUR
T1 - Transdermal drug delivery
T2 - 30 + years of war and still fighting!
AU - Wiedersberg, Sandra
AU - Guy, Richard H.
PY - 2014/9/28
Y1 - 2014/9/28
N2 - By any measure, transdermal drug delivery (TDD) is a successful controlled release technology. Over the last 30 + years, a steady flux of transdermal products have received regulatory approval and reached the market. For the right compounds, TDD is an effective and preferred route of administration; for others, delivery across the skin makes no sense at all. Currently, the "rules" that govern (passive) TDD feasibility are clearly understood, and research activity is focused on novel approaches that strive to subvert skin's excellent barrier function, and broaden the range of active species amenable to percutaneous administration.
AB - By any measure, transdermal drug delivery (TDD) is a successful controlled release technology. Over the last 30 + years, a steady flux of transdermal products have received regulatory approval and reached the market. For the right compounds, TDD is an effective and preferred route of administration; for others, delivery across the skin makes no sense at all. Currently, the "rules" that govern (passive) TDD feasibility are clearly understood, and research activity is focused on novel approaches that strive to subvert skin's excellent barrier function, and broaden the range of active species amenable to percutaneous administration.
UR - http://www.scopus.com/inward/record.url?scp=84901386044&partnerID=8YFLogxK
UR - http://dx.doi.org/10.1016/j.jconrel.2014.05.022
U2 - 10.1016/j.jconrel.2014.05.022
DO - 10.1016/j.jconrel.2014.05.022
M3 - Article
SN - 0168-3659
VL - 190
SP - 150
EP - 156
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -